Evaluation of CD31 (PECAM-1) expression using tissue microarray in patients with renal cell carcinoma

Tumor Biology

Volumn 28, Issue 3, 2007, Pages 158-164

  Sandlund, Johanna ^a   Hedberg, Ylva ^a   Bergh, Anders ^a   Grankvist, Kjell ^a   Ljungberg, Börje ^a   Rasmuson, Torgny ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Angiogenesis; CD31; Microarray; Microvessel density; Nuclear grade; PECAM 1; Renal cell carcinoma; Tissue microarray

Indexed keywords

CD31 ANTIGEN;

ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 34250860638     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102980     Document Type: Article

References (31)

1. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
2. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
3. Wikström P, Lissbrant IF, Stattin P, Egevad L, Bergh A: Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002;51:268-275.
4. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zinke H: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663-1671.
5. Jackson DE: The unfolding tale of PECAM-1. FEBS Lett 2003;10:7-14.
6. Tanaka F, Otake Y, Yanagihara K , Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H: Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001;7:3410-3415.
7. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Charpin C: Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol 2004;35:176-183.
8. Sobin LH, Wittekind CH (eds): International Union against Cancer (UICC). TNM classification of malignant tumours, ed 6. New York, Wiley, 2002, pp 193-195.
9. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF: Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971;28:1165-1177.
10. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B: The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-133.
11. Lissbrant IF, Stattin P, Damber JE, Bergh A: Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997;33:38-45.
12. Herbst C, Kosmehl H, Stiller KJ, Berndt A, Eiselt M, Schubert J, Katenkamp D: Evaluation of microvessel density by computerised image analysis in human renal cell carcinoma. Correlation to pT category, nuclear grade, proliferative activity and occurrence of metastasis. J Cancer Res Clin Oncol 1998;124:141-147.
13. Kinouchi T, Mano M, Matsuoka I, Kodama S, Aoki T, Okamoto M, Yamamura H, Usami M, Takahashi K: Immature tumor angiogenesis in high-grade and high-stage renal cell carcinoma. Urology 2003;62:765-770.
14. Hemmerlein B, Galuschka L, Putzer N, Zischkau S, Heuser M: Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas. Histopathology 2004;45:603-611.
15. Imao T, Egawa M, Takashima H, Koshida K, Namiki M: Inverse correlation of microvessel density with metastasis and prognosis in renal cell carcinoma. Int J Urol 2004;11:948-953.
16. Delahunt B, Bethwaite PB, Thornton A: Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol 1997;80:401-404.
17. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, Rasmuson T: Endoglin (CD105) expression in human renal cell carcinoma. BJU Int 2006;97:706-710.
18. Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ: Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int 2004;93:291-296.
19. MacLennan GT, Bostwick DG: Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology 1995;46:27-30.
20. Yagasaki H, Kawata N, Takimoto Y, Nemoto N: Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol 2003;10:220-227.
21. Rioux-Leclercq N, Epstein JI, Bansard JY, Turlin B, Patard JJ, Manunta A, Chan T, Ramee MP, Lobel B, Moulinoux JP: Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol 2001;32:1209-1215.
22. Mattern J, Volm M: Microvessel density and vascular endothelial growth factor expression in human tumors of different localization. Oncol Rep 1996;3:465-468.
23. Mineo TC, Ambrogi V, Baldi A , Rabitti C, Bollero P, Vincenzi B, Tonini G: Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 2004;57:591-597.
24. Ljungberg B, Jacobsen J, Häggström-Rudolfsson S, Rasmuson T, Lindh G, Grankvist K: Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urol Res 2003;31:335-340.
25. Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-893.
26. Axelson H, Fredlund E, Ovenberger M, Landberg G, Påhlman S: Hypoxia-induced dedifferentiation of tumor cells - a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 2005;16:554-563.
27. Rak J, Yu JL: Oncogenes and tumor angiogenesis: the question of vascular 'supply' and vascular 'demand'. Semin Cancer Biol 2004;14:93-104.
28. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395-2400.
29. Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC, Kwon ED: Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005;104:511-520.
30. Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS: Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 2005;103:2517-2525.
31. Foria V, Surendra T, Poller DN: Prognostic relevance of extensive necrosis in renal cell carcinoma. J Clin Pathol 2005;58:39-43.